News for Regeneron Pharmaceuticals, Inc. (REGN34.SA)

July is observed as Sarcoma Awareness Month. Sarcoma is a rare type of cancer that affects muscles, fat, nerves, and other connective tissues. As we get ready to welcome July, it's also time to track the important FDA decisions lined up for the month.

Summary Regeneron Pharmaceuticals Inc (REGN), a leading biotechnology company, has announced that it will release its second quarter 2025 financial and operatin

TARRYTOWN, N.Y., June 26, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. ( REGN) today announced that it will report its second quarter 2025 financi

Regeneron Pharmaceuticals, Inc. faces challenges with Eylea sales but sees growth from Dupixent and obesity drugs. Click for my updated look at REGN.

Regeneron shows financial strength and fair valuation, but trevogrumab's Phase 2 progress adds uncertainty. Click here to read an analysis of REGN stock now.

REYKJAVIK, Iceland and LONDON, June 23, 2025 (GLOBE NEWSWIRE) -- Alvotech ( ALVO), a global biotech company specializing in the development and manufacture of

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is among the 11 Best Genomics Stocks to Buy According to Hedge Funds. UBS has maintained its Neutral rating on Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) and reduced its price objective from $633 to $560 on June 5, noting mixed corporate updates and recent pipeline advancements. The Phase 2 COURAGE study interim readout, […]

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is among the 11 Best Genomics Stocks to Buy According to Hedge Funds. UBS has maintained its Neutral rating on Regeneron Pharmaceuticals, Inc.

Quick Summary: Regeneron Pharmaceuticals and Sanofi receive FDA approval for Dupixent's expanded use. Analysts predict a significant upside for Regeneron

Regeneron Pharmaceuticals (REGN), in collaboration with Sanofi, has obtained approval from the U.S. Food and Drug Administration (FDA) for their drug Dupixent.

Summary Regeneron Pharmaceuticals Inc (REGN) and Sanofi have announced that the U.S. Food and Drug Administration (FDA) has approved Dupixent® (dupilumab) for

First FDA-approved targeted treatment for bullous pemphigoid, addressing an unmet medical need. Demonstrated 18.3% sustained disease remission rate comp

**media[659912]**

**media[659911]**

On June 10, 2025, Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) received a ‘Hold’ rating from Wells Fargo, which set the company’s stock price target at $580.

Regeneron Pharmaceuticals, Inc. (REGN) recently held its 2025 Annual Meeting of Shareholders on June 13, 2025, where several significant proposals were put to

Summary: Regeneron Pharmaceuticals (REGN) decides not to increase its acquisition offer for 23andMe. Analysts set an average price target for REGN at $73

In a notable development for Regeneron Pharmaceuticals (REGN) and Sanofi, the companies have disclosed positive outcomes from the EVEREST Phase 4 study involvin

TTAM Commits to Comply with Company's Privacy Policy and All Applicable Laws TTAM Commits to Adopting Additional Consumer Protections and Privacy Safeguards to